Fig. 4

LINC00152 increases the expression of ZEB1 through interaction with EZH2 in EC cells. a–b the mRNA expression of ZEB1 in EC tissues, Kyse-150 and TE-1 cells detected by RT-PCR assay. c the protein expression of ZEB1 in EC tissues, Kyse-150 and TE-1 cells determined by Western blot analysis. d Statistical histogram of panel C. e–f the enrichment of EZH2 and H3K27me3 in ZEB1 promoter region in Kyse-150 cells and TE-1 cells determined by ChIP assay. g–h the mRNA expression of ZEB1 in transfected Kyse-150 and TE-1 cells. i the protein expression of ZEB1 in transfected Kyse-150 and TE-1 cells; j–k Statistical histogram of panel I. l the mRNA expression of ZEB1 in Kyse-150 and TE-1 cells transfected with oe-ZEB1 or si-ZEB1. m the protein expression of ZEB1 in Kyse-150 and TE-1 cells transfected with oe-ZEB1 or si-ZEB1, n Statistical histogram of panel M. o–p cell survival rate after 72 h of treatment with different doses of L-OHP (0, 0.5, 1.0, 2.5, 5.0, 10.0 µM) in Kyse-150 and TE-1 cells detected by CCK-8 assay. q–t the protein expression of E-cadherin, vimentin, cleaved PARP and cleaved Caspase 3 protein after 72 h of treatment with 10.0 µM of L-OHP determined by Western blot analysis. In panel a–d, * p < 0.05 vs. normal adjacent tissues or Het-1A cells. In panel e-f, * p < 0.05 vs. the si-NC group. In g–k * p < 0.05 vs. the oe-NC + si-NC group, # p < 0.05 vs. the oe-LINC00152 group. In panel l–t, * p < 0.05 vs. the oe-NC group. # p < 0.05 vs. the oe-NC group. Paired data in compliance with normal distribution and homogeneity between cancer tissues and adjacent tissues were compared using paired t-test. Comparisons among multiple groups were conducted by ANOVA with Tukey’s post hoc test. Data at different time points and different concentrations were compared by repeated measures ANOVA. Data are presented as mean ± standard deviation of three technical replicates